Vanita Aroda, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1588748883
Payments from drug & device makers
Across 1,737 payments — averaging $2412.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.4M
- Novo Nordisk AS$1.1M
- AstraZeneca$377K
- Applied Therapeutics, Inc.$291K
- Novo Nordisk$291K
- Rhythm Pharmaceuticals, Inc.$185K
- plus $506K from 12 others
Across 46 payments — averaging $1746.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$56K
- Sanofi-aventis U.S. LLC$21K
- Sanofi US Services Inc.$2K
- Novo Nordisk AS$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 32 | $1,421,270 |
| Novo Nordisk AS | 1,291 | $1,118,544 |
| AstraZeneca | 25 | $377,170 |
| Applied Therapeutics, Inc. | 34 | $291,373 |
| Novo Nordisk | 135 | $291,196 |
| Rhythm Pharmaceuticals, Inc. | 22 | $184,980 |
| Boehringer Ingelheim | 26 | $145,054 |
| Amgen | 8 | $118,428 |
| Sanofi US Services Inc. | 21 | $105,683 |
| Pfizer | 19 | $64,067 |
| Servier Affaires Medicales | 1 | $18,500 |
| Astrazeneca AB | 6 | $18,124 |
| Sanofi-aventis U.S. LLC | 6 | $12,183 |
| Boehringer Ingelheim International GmbH | 91 | $11,025 |
| Corcept Therapeutics | 13 | $8,535 |
| F. Hoffmann-la Roche AG | 2 | $2,351 |
| Novo Nordisk Health Care AG | 1 | $2,000 |
| Merck | 4 | $334 |
How this compares
$4,190,818 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Boston
- David NathanBoston$9M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
- Christos MantzorosBoston$983K
- Benjamin LederBoston$912K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.